Cardinal Health, Inc.

CAH Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of CAH by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Sale $1,001 - $15,000 Jan 23, 2026
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Oct 24, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Sep 05, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 May 14, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 May 05, 2025
Robert Bresnahan House / R Purchase $1,001 - $15,000 Apr 08, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Mar 17, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Jan 21, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Sep 20, 2024
John James House / R Sale $1,001 - $15,000 Sep 04, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
John James House / R Purchase $1,001 - $15,000 Jun 03, 2024
John James House / R Purchase $1,001 - $15,000 May 02, 2024
Ro Khanna House / D Sale None Mar 05, 2024
Jonathan L. Jackson House / D Purchase $50,001 - $100,000 Jan 12, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 10, 2024
Ro Khanna House / D Sale Over $50,000,000 Sep 06, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 29, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Feb 10, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Jan 11, 2023
Kathy E. Manning House / D Sale $1,001 - $15,000 Aug 03, 2022
Kathy E. Manning House / D Purchase $1,001 - $15,000 Jul 20, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Nov 09, 2021
Ro Khanna House / D Sale $1,001 - $15,000 Nov 01, 2021
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Apr 07, 2020
Kelly Loeffler Senate / R Purchase $1,001 - $15,000 Apr 07, 2020
Kelly Loeffler Senate / R Sale (Full) $100,001 - $250,000 Apr 07, 2020
Kelly Loeffler Senate / R Purchase $100,001 - $250,000 Mar 20, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar 18, 2020
Ro Khanna House / D Purchase $1,001 - $15,000 Sep 16, 2019
Dean Phillips House / D Sale $1,001 - $15,000 Jun 20, 2019
Ro Khanna House / D Sale $1,001 - $15,000 Jun 03, 2019
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 29, 2019
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 23, 2019
Ro Khanna House / D Sale $1,001 - $15,000 Mar 26, 2019
Dean Phillips House / D Purchase $1,001 - $15,000 Feb 04, 2019
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 18, 2019
Ro Khanna House / D Sale $1,001 - $15,000 Dec 17, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 13, 2018
Ro Khanna House / D Sale $1,001 - $15,000 Jun 15, 2018
Ro Khanna House / D Sale $1,001 - $15,000 May 15, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 05, 2018
Bob Gibbs House / R Sale $1,001 - $15,000 Feb 27, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 28, 2017
Richard L. Hanna House / R Sale $100,001 - $250,000 Nov 17, 2017
CAH Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CAH Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CAH Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in CAH holdings by institutional investors

Insider Trading

Quarterly net insider trading by CAH's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $740,000 Jan 20, 2026 Issue: Health Issues Manufacturing Trade (domestic/foreign) Tariff (miscellaneous tariff bills)
  • $450,000 Oct 22, 2025 Issue: Tariff (miscellaneous tariff bills) Health Issues Manufacturing Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $390,000 Oct 17, 2025 Issue: Health Issues Manufacturing Trade (domestic/foreign) Tariff (miscellaneous tariff bills)
  • $1,070,000 Apr 21, 2025 Issue: Health Issues Manufacturing Taxation/Internal Revenue Code Trade (domestic/foreign) Tariff (miscellaneous tariff bills)
  • $500,000 Jan 17, 2025 Issue: Energy/Nuclear Health Issues Disaster Planning/Emergencies Manufacturing Civil Rights/Civil Liberties Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $220,000 Oct 18, 2024 Issue: Communications/Broadcasting/Radio/TV Taxation/Internal Revenue Code Civil Rights/Civil Liberties Manufacturing Disaster Planning/Emergencies Health Issues Energy/Nuclear
  • $720,000 Jul 19, 2024 Issue: Taxation/Internal Revenue Code Civil Rights/Civil Liberties Manufacturing Disaster Planning/Emergencies Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $410,000 Jan 22, 2024 Issue: Manufacturing Disaster Planning/Emergencies Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $220,000 Oct 18, 2023 Issue: Manufacturing Disaster Planning/Emergencies Civil Rights/Civil Liberties Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $200,000 Jul 20, 2023 Issue: Manufacturing Disaster Planning/Emergencies Civil Rights/Civil Liberties Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $410,000 Jan 20, 2023 Issue: Railroads Budget/Appropriations Manufacturing Disaster Planning/Emergencies Civil Rights/Civil Liberties Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $210,000 Oct 19, 2022 Issue: Budget/Appropriations Manufacturing Disaster Planning/Emergencies Civil Rights/Civil Liberties Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $260,000 Jul 20, 2022 Issue: Budget/Appropriations Manufacturing Disaster Planning/Emergencies Civil Rights/Civil Liberties Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $950,000 Apr 20, 2022 Issue: Budget/Appropriations Government Issues Manufacturing Disaster Planning/Emergencies Civil Rights/Civil Liberties Health Issues Tariff (miscellaneous tariff bills) Energy/Nuclear
  • $670,000 Jan 20, 2022 Issue: None
  • $390,000 Oct 19, 2021 Issue: None
  • $650,000 Jul 20, 2021 Issue: None
  • $780,000 Apr 20, 2021 Issue: None
  • $710,000 Jan 20, 2021 Issue: None
  • $560,000 Oct 20, 2020 Issue: None
  • $340,000 Jul 16, 2020 Issue: None
  • $950,000 Apr 20, 2020 Issue: None
  • $780,000 Jan 20, 2020 Issue: None
  • $620,000 Oct 18, 2019 Issue: Budget/Appropriations Health Issues Disaster Planning/Emergencies Civil Rights/Civil Liberties Alcohol and Drug Abuse Defense Tariff (miscellaneous tariff bills) Energy/Nuclear Medical/Disease Research/Clinical Labs
  • $550,000 Jul 17, 2019 Issue: Medical/Disease Research/Clinical Labs Tariff (miscellaneous tariff bills) Energy/Nuclear Disaster Planning/Emergencies Defense Alcohol and Drug Abuse Civil Rights/Civil Liberties Health Issues Budget/Appropriations
  • $780,000 Apr 18, 2019 Issue: Civil Rights/Civil Liberties Energy/Nuclear Tariff (miscellaneous tariff bills) Disaster Planning/Emergencies Defense Alcohol and Drug Abuse Health Issues Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $970,000 Jan 17, 2019 Issue: Medical/Disease Research/Clinical Labs Energy/Nuclear Budget/Appropriations Disaster Planning/Emergencies Alcohol and Drug Abuse Defense Health Issues Tariff (miscellaneous tariff bills)
  • $790,000 Oct 17, 2018 Issue: Medical/Disease Research/Clinical Labs Tariff (miscellaneous tariff bills) Energy/Nuclear Health Issues Taxation/Internal Revenue Code Alcohol and Drug Abuse Defense Budget/Appropriations Disaster Planning/Emergencies Veterans
  • $520,000 Jul 19, 2018 Issue: Medical/Disease Research/Clinical Labs Tariff (miscellaneous tariff bills) Budget/Appropriations Veterans Health Issues Disaster Planning/Emergencies Taxation/Internal Revenue Code Alcohol and Drug Abuse Defense Energy/Nuclear
  • $540,000 Apr 18, 2018 Issue: Taxation/Internal Revenue Code Defense Energy/Nuclear Budget/Appropriations Health Issues Veterans Medical/Disease Research/Clinical Labs Alcohol and Drug Abuse Disaster Planning/Emergencies
  • $520,000 Jan 18, 2018 Issue: Energy/Nuclear Health Issues Alcohol and Drug Abuse Disaster Planning/Emergencies Veterans Medical/Disease Research/Clinical Labs Defense Taxation/Internal Revenue Code
  • $500,000 Oct 18, 2017 Issue: Medical/Disease Research/Clinical Labs Disaster Planning/Emergencies Taxation/Internal Revenue Code Alcohol and Drug Abuse Defense Veterans Health Issues Energy/Nuclear
  • $360,000 Jul 17, 2017 Issue: Medical/Disease Research/Clinical Labs Energy/Nuclear Veterans Health Issues Taxation/Internal Revenue Code Alcohol and Drug Abuse
  • $370,000 Apr 19, 2017 Issue: Alcohol and Drug Abuse Energy/Nuclear Taxation/Internal Revenue Code Veterans Medical/Disease Research/Clinical Labs Health Issues
  • $290,000 Jan 19, 2017 Issue: Medical/Disease Research/Clinical Labs Energy/Nuclear Veterans Taxation/Internal Revenue Code Alcohol and Drug Abuse Health Issues
  • $340,000 Oct 17, 2016 Issue: Medical/Disease Research/Clinical Labs Energy/Nuclear Veterans Health Issues Alcohol and Drug Abuse Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $290,000 Jul 15, 2016 Issue: Medical/Disease Research/Clinical Labs Energy/Nuclear Veterans Taxation/Internal Revenue Code Alcohol and Drug Abuse Health Issues Trade (domestic/foreign)
  • $270,000 Apr 19, 2016 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Alcohol and Drug Abuse Trade (domestic/foreign) Medical/Disease Research/Clinical Labs Energy/Nuclear
  • $220,000 Jan 20, 2016 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Alcohol and Drug Abuse Trade (domestic/foreign) Energy/Nuclear Medical/Disease Research/Clinical Labs
  • $870,000 Oct 20, 2015 Issue: Medical/Disease Research/Clinical Labs Energy/Nuclear Taxation/Internal Revenue Code Alcohol and Drug Abuse Medicare/Medicaid
  • $310,000 Jul 20, 2015 Issue: Taxation/Internal Revenue Code Alcohol and Drug Abuse Medicare/Medicaid Medical/Disease Research/Clinical Labs Energy/Nuclear
  • $1,090,000 Apr 20, 2015 Issue: Energy/Nuclear Medicare/Medicaid Taxation/Internal Revenue Code Alcohol and Drug Abuse Medical/Disease Research/Clinical Labs
  • $260,000 Jan 19, 2015 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Alcohol and Drug Abuse Trade (domestic/foreign)
  • $780,000 Oct 21, 2014 Issue: Pharmacy Taxation/Internal Revenue Code Medicare/Medicaid
  • $410,000 Jul 21, 2014 Issue: Health Issues Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid
  • $620,000 Apr 19, 2014 Issue: Health Issues Taxation/Internal Revenue Code Pharmacy
  • $380,000 Jan 21, 2014 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code
  • $960,000 Oct 21, 2013 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code
  • $360,000 Jul 15, 2013 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code
  • $230,000 Apr 22, 2013 Issue: Health Issues Taxation/Internal Revenue Code Pharmacy
  • $310,000 Jan 21, 2013 Issue: Health Issues Taxation/Internal Revenue Code
  • $610,000 Oct 22, 2012 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code
  • $875,000 Jul 20, 2012 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code
  • $370,000 Apr 20, 2012 Issue: Pharmacy Health Issues
  • $235,000 Jan 20, 2012 Issue: Health Issues Pharmacy
  • $670,000 Oct 19, 2011 Issue: Health Issues Taxation/Internal Revenue Code Financial Institutions/Investments/Securities
  • $350,000 Jul 20, 2011 Issue: Health Issues Taxation/Internal Revenue Code
  • $180,000 Apr 20, 2011 Issue: Health Issues Medicare/Medicaid
  • $135,000 Jan 17, 2011 Issue: Medicare/Medicaid Health Issues
  • $540,000 Oct 20, 2010 Issue: Health Issues Medicare/Medicaid
  • $300,000 Jul 19, 2010 Issue: Health Issues Medicare/Medicaid
  • $320,000 Apr 19, 2010 Issue: Health Issues
  • $160,000 Jan 20, 2010 Issue: Health Issues
  • $390,000 Oct 19, 2009 Issue: Medicare/Medicaid Energy/Nuclear Health Issues
  • $190,000 Jul 19, 2009 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Pharmacy
  • $195,000 Apr 20, 2009 Issue: Medicare/Medicaid Pharmacy
  • $180,000 Jan 20, 2009 Issue: Homeland Security Pharmacy Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $320,000 Oct 20, 2008 Issue: Medical/Disease Research/Clinical Labs Homeland Security Pharmacy Medicare/Medicaid
  • $230,000 Jul 18, 2008 Issue: Homeland Security Medicare/Medicaid Pharmacy Medical/Disease Research/Clinical Labs
  • $200,000 Apr 18, 2008 Issue: Medicare/Medicaid Homeland Security Medical/Disease Research/Clinical Labs
  • $580,000 Feb 14, 2008 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $1,000,400 Aug 13, 2007 Issue: Medicare/Medicaid Pharmacy
  • $760,000 Aug 01, 2007 Issue: Manufacturing Health Issues Medicare/Medicaid Pharmacy Medical/Disease Research/Clinical Labs Science/Technology
  • $320,000 Aug 08, 2006 Issue: Medicare/Medicaid
  • $140,000 Feb 14, 2006 Issue: Medicare/Medicaid
  • $130,000 Aug 09, 2005 Issue: Manufacturing Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Pharmacy Science/Technology
  • $140,000 Feb 08, 2005 Issue: Manufacturing Health Issues Science/Technology Medicare/Medicaid Pharmacy Medical/Disease Research/Clinical Labs
  • $220,000 Aug 18, 2004 Issue: Manufacturing Medical/Disease Research/Clinical Labs Science/Technology Health Issues Medicare/Medicaid Pharmacy
  • $100,000 Apr 16, 2004 Issue: Medicare/Medicaid Manufacturing Health Issues Pharmacy Medical/Disease Research/Clinical Labs Science/Technology
  • $120,000 Aug 06, 2003 Issue: Pharmacy Medical/Disease Research/Clinical Labs Science/Technology Manufacturing Health Issues Medicare/Medicaid
  • $120,000 Mar 14, 2003 Issue: Science/Technology Manufacturing Health Issues Medicare/Medicaid Pharmacy Medical/Disease Research/Clinical Labs
  • $20,000 Aug 13, 2002 Issue: Manufacturing Medicare/Medicaid Pharmacy Medical/Disease Research/Clinical Labs Science/Technology
  • $40,000 Feb 28, 2002 Issue: Pharmacy Medical/Disease Research/Clinical Labs Science/Technology Medicare/Medicaid Manufacturing Health Issues
  • $60,000 Aug 13, 2001 Issue: Health Issues
  • $40,000 Feb 15, 2001 Issue: Health Issues Pharmacy Medical/Disease Research/Clinical Labs
  • $900,000 Aug 15, 2000 Issue: Health Issues
  • $80,000 Aug 09, 2000 Issue: Science/Technology Medical/Disease Research/Clinical Labs Pharmacy Medicare/Medicaid Health Issues Manufacturing
  • $60,000 Feb 14, 2000 Issue: Science/Technology Manufacturing Health Issues Medicare/Medicaid Pharmacy Medical/Disease Research/Clinical Labs
  • $80,000 Feb 14, 2000 Issue: Health Issues
  • $820,000 Aug 13, 1999 Issue: Health Issues
Corporate Lobbying

CAH Estimated quarterly lobbying spending

Revenue Breakdown

CAH Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CAH Income Statement
CAH Balance Sheet
CAH Cash Flow
U.S. Patents

New CAH patent grants

  • Patent Title: Pharmaceutical distribution systems and methods May. 17, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to CAH from public contracts

CAH News

Recent insights relating to CAH

CNBC Recommendations

Recent picks made for CAH stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CAH

CAH Analyst Ratings

CAH Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CAH Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CAH stock a Buy, Sell, or Hold?

  • What is the price target for $CAH stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CAH Top Shareholders
Shareholder
Shares Held
CAH Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CAH stock?

  • Who owns the most shares of $CAH stock?

  • What funds own $CAH stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CAH Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CAH Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About CAH

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

  • Address Dublin, OH
  • Market Cap 52.5 billion
  • Employees 57,700
  • Industrial Classification Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cardinal Health, Inc. Executive Compensation
Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation